Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Emergent BioSolutions the Next Hot Coronavirus Stock?


When it comes to hot coronavirus stocks, investors have likely heard a lot about the many potential vaccines and other treatments currently being developed. However, there is one company working in the COVID-19 vaccine market that hasn't gotten much attention in comparison with some of its peers.

That business is Emergent BioSolutions (NYSE: EBS), a biotech company that specializes in developing vaccines and antibody therapies. The company recently ended up grabbing quite a bit of investor attention thanks to a recently announced partnership with Johnson & Johnson (NYSE: JNJ) to help manufacture the latter's COVID-19 vaccine. 

Nor is this the first COVID-19-related deal that Emergent has signed. Over the past month, the company has signed agreements with a number of other COVID-19 vaccine makers as well. Does all this make Emergent BioSolutions the next hot coronavirus stock, one you should keep on your watch list?

Continue reading


Source Fool.com

Like: 0
EBS
Share

Comments